

Clinical Policy: Dupilumab (Dupixent)

Reference Number: CP.PHAR.336

Effective Date: 06.01.17

Last Review Date: 02.25

Line of Business: Medicaid*

[Coding Implications](#)
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Dupilumab (Dupixent[®]) is an interleukin-4 receptor and interleukin-13 alpha antagonist.

** NY CHIP Plans should not be approved using these criteria; for NY CHIP Plans refer to the NY.HIM.SP69 Dupilumab (Dupixent) criteria*

FDA Approved Indication(s)

Dupixent is indicated:

- For the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
- As an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
- As an add-on maintenance treatment in adult and pediatric patients aged 12 and older with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
- For the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
- For the treatment of adult patients with prurigo nodularis (PN).
- As an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
- For the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.
- For the treatment of adult patients with bullous pemphigoid (BP).

Limitation(s) of use: Not for the relief of acute bronchospasm or status asthmaticus. Not indicated for other forms of urticaria.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Dupixent is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Atopic Dermatitis* (must meet all):

**Refer to NY.HIM.SP69 for NY CHIP Plans*

1. Diagnosis of atopic dermatitis affecting one of the following (a or b):
 - a. At least 10% of the member's body surface area (BSA);
 - b. Hands, feet, face, neck, scalp, genitals/groin, and/or intertriginous areas;
2. Prescribed by or in consultation with a dermatologist or allergist;
3. Age $\geq$ 6 months;
4. Failure of both of the following (a and b), unless contraindicated or clinically significant adverse effects are experienced:
 - a. Two formulary medium to very high potency topical corticosteroids of different molecular identities, each used for $\geq$ 2 weeks;
 - b. One non-steroidal topical therapy* used for $\geq$ 4 weeks: topical calcineurin inhibitor (e.g., tacrolimus 0.03% ointment, pimecrolimus 1% cream) or Eucrisa[®];
**These agents may require prior authorization*
5. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry[™], Cinqair[®], Fasenra[®], Nucala[®], Tezspire[™], Xolair[®]) or a Janus kinase (JAK) inhibitor (e.g., Olumiant[®], Rinvoq[®], Cibinco[®], Opzelura[™]);
6. Dose does not exceed one of the following (a, b, or c):
 - a. Age 6 months to 5 years and weight 5 to $<$ 15 kg: 200 mg every 4 weeks;
 - b. Age 6 months to 5 years and weight 15 to $<$ 30 kg: 300 mg every 4 weeks;
 - c. Age $\geq$ 6 years and the following:
 - i. Initial (one-time) dose:
 - 1) Age $\geq$ 18 years, weight $\geq$ 60 kg, or age 6-17 years and weight 15 to $<$ 30 kg: 600 mg;
 - 2) Age 6-17 years and weight 30 to $<$ 60 kg: 400 mg;
 - ii. Maintenance dose:
 - 1) Age $\geq$ 18 years or weight $\geq$ 60 kg: 300 mg every other week;
 - 2) Age 6-17 years and weight 30 to $<$ 60 kg: 200 mg every other week;
 - 3) Age 6-17 years and weight 15 to $<$ 30 kg: 300 mg every 4 weeks.

Approval duration: 6 months

B. Asthma* (must meet all):

**Refer to NY.HIM.SP69 for NY CHIP Plans*

1. Diagnosis of asthma and one of the following (a or b):
 - a. Absolute blood eosinophil count $\geq$ 150 cells/mcL within the past 3 months;
 - b. Currently receiving maintenance treatment with systemic glucocorticoids and has received treatment for at least 4 weeks;
2. Prescribed by or in consultation with an allergist, immunologist, or pulmonologist;
3. Age $\geq$ 6 years;
4. Member has experienced $\geq$ 2 exacerbations within the last 12 months, requiring one of the following (a or b), despite adherent use of controller therapy (i.e., medium- to high-dose inhaled corticosteroid [ICS] plus either a long-acting beta2 agonist [LABA] or leukotriene modifier [LTRA] if LABA contraindication/intolerance):
 - a. Oral/systemic corticosteroid treatment (or increase in dose if already on oral corticosteroid);

- b. Urgent care/emergency room (ER) visit or hospital admission;
- 5. Dupixent is prescribed concurrently with an ICS plus either a LABA or LTRA;
- 6. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenna, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
- 7. Dose does not exceed the following:
 - a. Initial (one-time) dose for age ≥ 12 years: 600 mg;
 - b. Maintenance dose:
 - i. Age ≥ 12 years: 300 mg every other week;
 - ii. Age 6-11 years and weight ≥ 30 kg: 200 mg every other week;
 - iii. Age 6-11 years and weight 15 to < 30 kg: 300 mg every 4 weeks.

Approval duration: 6 months

C. Chronic Rhinosinusitis with Nasal Polyposis* (must meet all):

**Refer to NY.HIM.SP69 for NY CHIP Plans*

- 1. Diagnosis of CRSwNP with documentation of all of the following (a, b, and c):
 - a. Presence of nasal polyps;
 - b. Disease is bilateral;
 - c. Member has experienced signs and symptoms (e.g., nasal congestion/blockage/obstruction, loss of smell, rhinorrhea) for ≥ 12 weeks;
- 2. Prescribed by or in consultation with an allergist, immunologist, or otolaryngologist;
- 3. Age ≥ 12 years;
- 4. Member has required the use of systemic corticosteroids for symptom control within the last 2 years, unless contraindicated or clinically significant adverse effects are experienced (*see Appendix B for examples*);
- 5. Failure of maintenance therapy with at least two intranasal corticosteroids, one of which must be Xhance[™] in adults, each used for ≥ 4 weeks, unless contraindicated or clinically significant adverse effects are experienced (*see Appendix B for examples*);
- 6. Dupixent is prescribed concurrently with an intranasal corticosteroid, unless contraindicated or clinically significant adverse effects are experienced (*see Appendix B for examples*);
- 7. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenna, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
- 8. Dose does not exceed 300 mg every other week.

Approval duration: 6 months

D. Eosinophilic Esophagitis (must meet all):

- 1. Diagnosis of EoE confirmed by ≥ 15 intraepithelial eosinophils per high-power field (eos/hpf) on endoscopic biopsy;
- 2. Prescribed by or in consultation with an allergist, immunologist, or gastroenterologist;
- 3. Age ≥ 1 year;
- 4. Weight ≥ 15 kg;
- 5. Member does not have hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome);

6. Failure of one of the following (a or b), unless clinically significant adverse effects are experienced or both are contraindicated:
 - a. Proton pump inhibitor (*see Appendix B for examples*);
 - b. Corticosteroid (*see Appendix B for examples*);
7. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasentra, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
8. Dose does not exceed the following:
 - a. Weight 15 to < 30 kg: 200 mg every other week;
 - b. Weight 30 to < 40 kg: 300 mg every other week;
 - c. Weight $\geq$ 40 kg: 300 mg every week.

Approval duration: 6 months

E. Prurigo Nodularis (must meet all):

1. Diagnosis of PN with documentation of both of the following (a and b, *see Appendix F*):
 - a. Numeric rating scale $\geq$ 7 on a scale of 0 (“no itch”) to 10 (“worst imaginable itch”) (e.g., Peak Pruritus Numeric Rating Scale, Worst Itch-Numeric Rating Scale);
 - b. $\geq$ 20 nodular lesions total on both legs, and/or both arms and/or trunk;
2. Prescribed by or in consultation with a dermatologist;
3. Age $\geq$ 18 years;
4. Failure of a $\geq$ 2-week course of a medium to very high potency topical corticosteroid, unless contraindicated or clinically significant adverse effects are experienced;
5. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasentra, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
6. Dose does not exceed the following:
 - a. Initial (one-time) dose: 600 mg;
 - b. Maintenance dose: 300 mg every other week.

Approval duration: 6 months

F. Chronic Obstructive Pulmonary Disease (must meet all):

1. Diagnosis of COPD as evidenced by one of the following (a or b):
 - a. Postbronchodilator ratio of the forced expiratory volume in 1 second (FEV₁)/forced vital capacity (FVC) < 0.7 ;
 - b. Postbronchodilator FEV₁ ≥ 20 % and ≤ 80 % of predicted normal;
2. Age $\geq$ 18 years;
3. Documentation of eosinophilic phenotype with blood eosinophil count of ≥ 300 cells/ μ L;
4. Member has history of ≥ 2 moderate or ≥ 1 severe exacerbations within the past 12 months;
5. Member meets one of the following (a or b, *see Appendix B*), unless clinically significant adverse effects are experienced or all are contraindicated:

- a. Failure of triple inhaled therapy consisting of a combination of LABA + long-acting antimuscarinic antagonist (LAMA) + ICS, at up to maximally indicated doses for ≥ 3 months;
- b. If member is contraindicated to ICS, failure of dual inhaled therapy consisting of a combination of LABA + LAMA, at up to maximally indicated doses for ≥ 3 months;
6. Provider attestation that member is concomitantly receiving triple therapy maintenance (e.g., LABA + LAMA + ICS) or double therapy maintenance (e.g., LABA + LAMA) if ICS is contraindicated;
7. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenna, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
8. Dose does not exceed 300 mg every other week.

Approval duration: 6 months

G. Chronic Spontaneous Urticaria (must meet all):

1. Diagnosis of CSU;
2. Prescribed by or in consultation with a dermatologist, immunologist, or allergist;
3. Age ≥ 12 years;
4. Failure of both of the following, unless clinically significant adverse effects are experienced or all are contraindicated (a and b):
 - a. Two antihistamines (including one second generation antihistamine – e.g., cetirizine, levocetirizine, fexofenadine, loratadine, desloratadine) at maximum indicated doses, each used for ≥ 2 weeks;
 - b. A LTRA in combination with an antihistamine at maximum indicated doses for ≥ 2 weeks;
5. Member has not received prior anti-IgE treatment (e.g., Xolair) for CSU;
6. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenna, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
7. Dose does not exceed one of the following (a or b):
 - a. Age ≥ 18 years, both of the following (i and ii):
 - i. Initial (one-time) dose: 600 mg;
 - ii. Maintenance dose: 300 mg every other week;
 - b. Age 12-17 years, both of the following (i and ii):
 - i. Initial (one-time) dose (1 or 2):
 - 1) Weight ≥ 60 kg: 600 mg;
 - 2) Weight 30 to < 60 kg: 400 mg;
 - ii. Maintenance dose (1 or 2):
 - 1) Weight ≥ 60 kg: 300 mg every other week;
 - 2) Weight 30 to < 60 kg: 200 mg every other week.

Approval duration: 6 months

H. Bullous Pemphigoid (must meet all):

1. Diagnosis of BP;

2. Diagnosis is confirmed histologically, serologically (e.g., anti-BP180 IgG autoantibodies and/or anti-BP230 IgG autoantibodies by ELISA), or by immunofluorescence;
3. Prescribed by or in consultation with a dermatologist;
4. Age $\geq$ 18 years;
5. Inadequate response to at least one corticosteroid (e.g., prednisone) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
6. Failure of at least one non-steroidal immunosuppressive agent (e.g., azathioprine, mycophenolate mofetil, methotrexate) (*see Appendix B*) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
7. Prescribed in combination with a tapering course of oral corticosteroid;
8. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenra, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
9. Dose does not exceed both of the following (a and b):
 - a. Initial (one-time) dose: 600 mg;
 - b. Maintenance dose: 300 mg every other week.

Approval duration: 6 months

I. Immunotherapy-related Pruritus (off-label) (must meet all):

1. Diagnosis of immune checkpoint inhibitor-related toxicity that is one of the following (a or b; *see Appendix E*):
 - a. Pruritus that is severe (G3);
 - b. Bullous dermatitis that is moderate (G2), severe (G3), or life-threatening (G4);
2. Prescribed by or in consultation with an oncologist;
3. For severe (G3) pruritus, member has not responded to a gabapentinoid (e.g., gabapentin, pregabalin) after 1 month of therapy;
4. For moderate (G2) bullous dermatitis, member has not responded to $\geq$ 3 days of prednisone or methylprednisolone;
5. Dupixent is not prescribed concurrently with Cinqair, Fasenra, Nucala, Xolair, or Tezspire;
6. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 6 months

J. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or

- b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Atopic Dermatitis* (must meet all):

**Refer to NY.HIM.SP69 for NY CHIP Plans*

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy as evidenced by, including but not limited to, reduction in itching and scratching;
3. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenra, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinco, Opzelura);
4. If request is for a dose increase, new dose does not exceed:
 - a. Age $\geq$ 18 years or weight $\geq$ 60 kg: 300 mg every other week;
 - b. Age 6-17 years and weight 30 to $<$ 60 kg: 200 mg every other week;
 - c. Age 6-17 years and weight 15 to $<$ 30 kg: 300 mg every 4 weeks;
 - d. Age 6 months to 5 years and weight 5 to $<$ 15 kg: 200 mg every 4 weeks;
 - e. Age 6 months to 5 years and weight 15 to $<$ 30 kg: 300 mg every 4 weeks.

Approval duration: 12 months

B. Asthma* (must meet all):

**Refer to NY.HIM.SP69 for NY CHIP Plans*

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Demonstrated adherence to asthma controller therapy (an ICS plus either a LABA or LTRA) as evidenced by proportion of days covered (PDC) of 0.8 in the last 6 months (i.e., member has received asthma controller therapy for at least 5 of the last 6 months);
3. Member is responding positively to therapy (examples may include but are not limited to: reduction in exacerbations or corticosteroid dose, improvement in forced expiratory volume over one second since baseline, reduction in the use of rescue therapy);

4. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenra, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
5. If request is for a dose increase, new dose does not exceed:
 - a. Age $\geq$ 12 years: 300 mg every other week;
 - b. Age 6-11 years and weight $\geq$ 30 kg: 200 mg every other week;
 - c. Age 6-11 years and weight 15 to $<$ 30 kg: 300 mg every 4 weeks.

Approval duration: 12 months

C. Chronic Rhinosinusitis with Nasal Polyposis* (must meet all):

**Refer to NY.HIM.SP69 for NY CHIP Plans*

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Demonstrated adherence to an intranasal corticosteroid, unless contraindicated or clinically significant adverse effects are experienced;
3. Member is responding positively to therapy (examples may include but are not limited to: reduced nasal polyp size, reduced need for systemic corticosteroids, improved sense of smell, improved quality of life);
4. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenra, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
5. If request is for a dose increase, new dose does not exceed 300 mg every other week.

Approval duration: 12 months

D. Eosinophilic Esophagitis (must meet all):

1. Currently meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy (examples may include but are not limited to: reduced eos/hpf count, improvement in dysphagia symptoms);
3. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenra, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
4. If request is for a dose increase, new dose does not exceed the following:
 - a. Weight 15 to $<$ 30 kg: 200 mg every other week;
 - b. Weight 30 to $<$ 40 kg: 300 mg every other week;
 - c. Weight $\geq$ 40 kg: 300 mg every week.

Approval duration: 12 months

E. Prurigo Nodularis (must meet all):

1. Currently meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy (examples may include but are not limited to: improvement in itching or skin pain, reduction in number of nodules);
3. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenna, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
4. If request is for a dose increase, new dose does not exceed 300 mg every other week.

Approval duration: 12 months

F. Chronic Obstructive Pulmonary Disease (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenna, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
4. If request is for a dose increase, new dose does not exceed 300 mg given every other week.

Approval duration: 12 months

G. Chronic Spontaneous Urticaria (must meet all)

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenna, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
4. If request is for a dose increase, new dose does not exceed the following:
 - a. Age $\geq$ 18 years or weight $\geq$ 60 kg: 300 mg every other week;
 - b. Age 12-17 years and weight 30 to $<$ 60 kg: 200 mg every other week.

Approval duration: 12 months

H. Bullous Pemphigoid (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. Dupixent is not prescribed concurrently with another biologic immunomodulator (e.g., Adbry, Cinqair, Fasenna, Nucala, Tezspire, Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, Opzelura);
4. If request is for a dose increase, new dose does not exceed 300 mg given every other week.

Approval duration: 12 months

I. Immunotherapy-related Pruritus (off-label) (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Dupixent for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months

J. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents;
- B. Acute bronchospasm or status asthmaticus.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ADL: activity of daily living
BP: bullous pemphigoid
CRSwNP: chronic rhinosinusitis with nasal polyposis
CSU: chronic spontaneous urticaria
EoE: eosinophilic esophagitis
eos/hpf: eosinophils per high-power field
FDA: Food and Drug Administration
GINA: Global Initiative for Asthma

ICS: inhaled corticosteroid
IgG: immunoglobulin G
JAK: Janus kinase
LABA: long-acting beta₂ agonist
LTRA: leukotriene modifier
PDC: proportion of days covered
PN: prurigo nodularis
WI-NRS: Worst Itch-Numeric Rating Scale

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
ATOPIC DERMATITIS, PN, BP		
Very High Potency Topical Corticosteroids		
augmented betamethasone 0.05% (Diprolene [®] AF) cream, ointment, gel, lotion	Apply topically to the affected area(s) BID	Varies
clobetasol propionate 0.05% (Temovate [®]) cream, ointment, gel, solution		
diflorasone diacetate 0.05% (Maxiflor [®] , Psorcon E [®]) cream, ointment		
fluocinonide 0.1% cream		
flurandrenolide 4 mcg/cm ² tape		
halobetasol propionate 0.05% (Ultravate [®]) cream, ointment		
High Potency Topical Corticosteroids		
amcinonide 0.1% ointment, lotion	Apply topically to the affected area(s) BID	Varies
augmented betamethasone 0.05% (Diprolene [®] AF) cream, ointment, gel, lotion		
betamethasone valerate 0.1%, 0.12% (Luxiq [®]) ointment, foam		
clobetasol propionate 0.025% (Impovz [®]) cream		

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
diflorasone 0.05% (Florone [®] , Florone E [®] , Maxiflor [®] , Psorcon E [®]) cream fluocinonide acetone 0.05% (Lidex [®] , Lidex E [®]) cream, ointment, gel, solution fluticasone propionate 0.005% cream, ointment halcinonide 0.1% cream, ointment, solution (Halog [®]) halobetasol propionate 0.01% lotion (Bryhali [®]) mometasone furoate 0.1% ointment triamcinolone acetone 0.5% (Aristocort [®] , Kenalog [®]) cream, ointment		
Medium Potency Topical Corticosteroids		
clocortolone pivalate 0.1% cream desoximetasone 0.05%, 0.25% (Topicort [®]) cream, ointment, gel, spray fluocinolone acetone 0.025% (Synalar [®]) cream, ointment flurandrenolide 0.05% lotion, ointment (Cordran [®]) hydrocortisone valerate 0.2% cream mometasone 0.1% (Elocon [®]) cream, ointment, lotion triamcinolone acetone 0.025%, 0.1% (Aristocort [®] , Kenalog [®]) cream, ointment	Apply topically to the affected area(s) BID	Varies
Other Classes of Agents		
Protopic [®] (tacrolimus), Elidel [®] (pimecrolimus)	Children ≥ 2 years and adults: Apply a thin layer topically to affected skin BID. Treatment should be discontinued if resolution of disease occurs.	Varies
Eucrisa [®] (crisaborole)	Atopic dermatitis: Apply to the affected areas BID	Varies
cyclosporine	3-6 mg/kg/day PO BID	300 mg/day
azathioprine	1-3 mg/kg/day PO QD	Weight-based

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
methotrexate	7.5-25 mg/wk PO once weekly	25 mg/week
mycophenolate mofetil	1-1.5 g PO BID	3 g/day
ASTHMA		
ICS (medium – high dose)		
Qvar [®] (beclomethasone)	> 100 mcg/day 40 mcg, 80 mcg per actuation 1-4 actuations BID	4 actuations BID
budesonide (Pulmicort [®])	> 200 mcg/day 90 mcg, 180 mcg per actuation 2-4 actuations BID	2 actuations BID
Alvesco [®] (ciclesonide)	> 80 mcg/day 80 mcg, 160 mcg per actuation 1-2 actuations BID	2 actuations BID
fluticasone propionate (Flovent [®])	> 100 mcg/day 44-250 mcg per actuation 2-4 actuations BID	2 actuations BID
Arnuity Ellipta [®] (fluticasone furoate)	≥ 50 mcg/day 100 mcg, 200 mcg per actuation 1 actuation QD	1 actuation QD
Asmanex [®] (mometasone)	> 100 mcg/day HFA: 100 mcg, 200 mcg per actuation Twisthaler: 110 mcg, 220 mcg per actuation 1-2 actuations QD to BID	2 inhalations BID
LABA		
Serevent [®] (salmeterol)	50 mcg per dose 1 inhalation BID	1 inhalation BID
Combination Products (ICS + LABA)		
Dulera [®] (mometasone/formoterol)	100/5 mcg, 200/5 mcg per actuation 2 actuations BID	4 actuations per day
Breo Ellipta [®] (fluticasone/vilanterol)	100/25 mcg, 200/25 mcg per actuation 1 actuation QD	1 actuation QD
fluticasone/ salmeterol (Advair [®])	Diskus: 100/50 mcg, 250/50 mcg, 500/50 mcg per actuation HFA: 45/21 mcg, 115/21 mcg, 230/21 mcg per actuation 1 actuation BID	1 actuation BID
fluticasone/salmeterol (Airduo RespiClick [®])	55/13 mcg, 113/14 mcg, 232/14 mcg per actuation 1 actuation BID	1 actuation BID

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
budesonide/ formoterol (Symbicort®)	80 mcg/4.5 mcg, 160 mcg/4.5 mcg per actuation 2 actuations BID	2 actuations BID
LTRA		
montelukast (Singulair®)	4 to 10 mg PO QD	10 mg per day
zafirlukast (Accolate®)	10 to 20 mg PO BID	40 mg per day
zileuton ER (Zyflo® CR)	1,200 mg PO BID	2,400 mg per day
Zyflo® (zileuton)	600 mg PO QID	2,400 mg per day
Oral Corticosteroids		
dexamethasone (Decadron®)	0.75 to 9 mg/day PO in 2 to 4 divided doses	Varies
methylprednisolone (Medrol®)	40 to 80 mg PO in 1 to 2 divided doses	Varies
prednisolone (Millipred®, Orapred ODT®)	40 to 80 mg PO in 1 to 2 divided doses	Varies
prednisone (Deltasone®)	40 to 80 mg PO in 1 to 2 divided doses	Varies
CRSwNP		
Intranasal Corticosteroids		
beclomethasone (Beconase AQ®, Qnasl®)	1-2 sprays IN BID	2 sprays/nostril BID
budesonide (Rhinocort® Aqua, Rhinocort®)	128 mcg IN QD or 200 mcg IN BID	1-2 inhalations/ nostril/day
flunisolide	2 sprays IN BID	2 sprays/nostril TID
fluticasone propionate (Flonase®)	1-2 sprays IN BID	2 sprays/nostril BID
mometasone (Nasonex®)	2 sprays IN BID	2 sprays/nostril BID
Omnanis®, Zetonna® (ciclesonide)	Omnanis: 2 sprays IN QD Zetonna: 1 spray IN QD	Omnanis: 2 sprays/ nostril/day Zetonna: 2 sprays/ nostril/day
triamcinolone (Nasacort®)	2 sprays IN QD	2 sprays/ nostril/day
Xhance™ (fluticasone propionate)	1 to 2 sprays (93 mcg/spray) to nostril IN BID	744 mcg/day
Oral Corticosteroids		
dexamethasone (Decadron®)	0.75 to 9 mg/day PO in 2 to 4 divided doses	Varies
methylprednisolone (Medrol®)	4 to 48 mg PO in 1 to 2 divided doses	Varies
prednisolone (Millipred®, Orapred ODT®)	5 to 60 mg PO in 1 to 2 divided doses	Varies
prednisone (Deltasone®)	5 to 60 mg PO in 1 to 2 divided doses	Varies

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
EoE		
Corticosteroids: examples – • <u>Topical</u>: ○ Budesonide administered as an oral viscous slurry of budesonide inhalation suspension [Pulmicort Respules®] with sucralose or similar carrier vehicle ○ Fluticasone propionate administered using a metered dose inhaler • <u>Oral</u>: ○ Prednisone	Varies	Varies
Proton pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole)	Varies	Varies
COPD		
ICS/LABA Combinations		
fluticasone/salmeterol (Advair Diskus®)	Refer to prescribing information	Refer to prescribing information
Breo Ellipta® (fluticasone/vilanterol)		
budesonide/formoterol (Symbicort®)		
Dulera®* (mometasone/formoterol)	Doses of 10 mcg formoterol/400 mcg mometasone and 10 mcg formoterol/ 200 mcg mometasone, each inhaled BID, have been studied	The optimal dose has not been established
LABA/LAMA Combinations		
Bevespi Aerosphere® (formoterol/glycopyrrolate)	Refer to prescribing information	Refer to prescribing information
Utibron Neohaler® (indacaterol/glycopyrrolate)		
Anoro Ellipta® (vilanterol/umeclidinium)		
Stiolto Respimat® (olodaterol/tiotropium)		
LAMAs		
Tudorza Pressair®	Refer to prescribing information	

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
(aclidinium bromide)		Refer to prescribing information
Seebri Neohlaer [®]		
(glycopyrrolate)		
Spiriva Respimat [®] / HandiHaler [®] (tiotropium)		
Incruse Ellipta [®] (umeclidinium)		
LABAs		
Brovana [®] (arformoterol)	Refer to prescribing information	Refer to prescribing information
Arcapta Neohaler [®] (indacaterol)		
Striverdi Respimat [®] (olodaterol)		
Serevent Diskus [®] (salmeterol)		
ICS/LABA/LAMA Combinations		
Trelegy [™] Ellipta [®] (fluticasone/umeclidinium/ vilanterol)	1 inhalation by mouth QD	1 inhalation/day
IMMUNOTHERAPY-RELATED MODERATE (G2) BULLOUS DERMATITIS		
corticosteroids: examples – prednisone, IV methylprednisolone	1-2 mg/kg/day Treat until symptoms improve to Grade ≤ 1, then taper over 4– 6 weeks.	Varies
CSU		
hydroxyzine (Vistaril [®])	Adult: 25 mg PO TID to QID Age ≥ 6 years: 50 mg-100 mg/day in divided doses	Adult: Will vary according to condition Age ≥ 6 years: 50 mg-100 mg/day in divided doses
diphenhydramine (Benadryl [®])	Adult: 25 mg to 50 mg PO TID to QID Pediatric: 12.5 mg to 25 mg PO TID to QID or 5 mg/kg/day or 150 mg/m ² /day	Adult: Will vary according to condition Children: 300 mg/day
chlorpheniramine (Aller- Chlor [®])	Immediate Release: 4 mg PO every 4 to 6 hours Extended Release: 12 mg PO every 12 hours	Do not exceed 24 mg/day
cetirizine (Zyrtec [®])	5 to 10 mg PO QD	10 mg/day
levocetirizine (Xyzal [®])	2.5 mg to 5 mg PO QD	5 mg/day
loratadine (Claritin [®])	10 mg PO QD	10 mg/day
desloratadine (Clarinex [®])	5 mg PO QD	Will vary according to condition
fexofenadine (Allegra [®])	60 mg PO BID or 180 mg QD	180 mg/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

**Off-label*

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): known hypersensitivity to Dupixent or any of its excipients
- Boxed warning(s): none reported

Appendix D: General Information

- Atopic dermatitis
 - The Phase III pivotal studies (SOLO 1 and SOLO 2) of Dupixent showed no significant difference in clinical outcomes between dosing of Dupixent every week and every other week for the treatment of atopic dermatitis.
- Asthma
 - During clinical trials (LIBERTY ASTHMA QUEST), among patients with a baseline blood eosinophil count of < 150 per cubic millimeter, the exacerbation rate was similar with dupilumab and with placebo: 0.47 (95% CI, 0.36 to 0.62) with lower-dose dupilumab and 0.51 (95% CI, 0.35 to 0.76) with matched placebo, and 0.74 (95% CI, 0.58 to 0.95) with higher-dose dupilumab and 0.64 (95% CI, 0.44 to 0.93) with matched placebo.
 - The Global Initiative for Asthma (GINA) guidelines for difficult-to-treat and severe asthma recommend Dupixent be considered as adjunct therapy for patients 6 years of age and older with exacerbations or poor symptom control despite taking at least high dose ICS/LABA and who have eosinophilic biomarkers or need maintenance oral corticosteroids.
 - Patients could potentially meet asthma criteria for both Xolair and Dupixent, though there is insufficient data to support the combination use of multiple asthma biologics. The combination has not been studied. Approximately 30% of patients in the Nucala MENSA study also were candidates for therapy with Xolair.
 - Lab results for blood eosinophil counts can be converted into cells/mcL using the following unit conversion calculator: <https://www.fasenrahcp.com/eosinophil-calculator>
 - PDC is a measure of adherence. PDC is calculated as the sum of days covered in a time frame divided by the number of days in the time frame. To achieve a PDC of 0.8, a member must have received their asthma controller therapy for 144 days out of the last 180 days, or approximately 5 months of the last 6 months.
- CSU:
 - CSU is classified as spontaneous onset of wheals, angioedema, or both, for more than 6 weeks due to an unknown cause.
 - Clinical studies have shown that dupilumab significantly improved the signs and symptoms of chronic idiopathic urticaria compared to placebo in patients who had remained symptomatic despite the use of approved dose of H₁- antihistamine. Dupilumab was also studied in patients who remained symptomatic despite H₁- antihistamine and anti-IgE treatments (CUPID Study B), but did not meet statistical significance for reduction in the primary endpoint Itch Severity Score over 7 days (ISS7) at Week 24.
 - Dupilumab for CSU is not currently included in clinical guideline treatment algorithms.

- The 2014 Joint Task Force on Practice Parameters representing various American allergy organizations include omalizumab in combination with H₁-antihistamines as a fourth line treatment option following a stepwise approach starting with a second generation antihistamine. This is followed by one or more of the following: a dose increase of the second generation antihistamine, or the addition of another second generation antihistamine, H₂-antagonist, LTRA, or first generation antihistamine. Treatment with hydroxyzine or doxepin can be considered in patients whose symptoms remain poorly controlled.
- The EAACI/GA2LEN/EDF/AAAAI/WAO Guideline for the Management of Urticaria include omalizumab in combination with H₁-antihistamines as a third line treatment option in patients who have failed to respond to higher doses of H₁- antihistamines.
- The use of over-the-counter H₁ antihistamines may not be a benefit to the treatment of CSU. Credit will be given for their use, but will not be covered under plan.

Appendix E: Immunotherapy-related Pruritus

- Immunotherapy refers to immune checkpoint inhibitors. Immune checkpoint inhibitors comprise a class of agents that target immune cell checkpoints, such as programmed cell death-1 (PD-1; e.g., Opdivo[®], Keytruda[®]) and PD-1 ligand (PD-L1; e.g., Tecentriq[®], Bavencio[®], Imfinzi[®]), as well as cytotoxic T-lymphocyte-associated antigen 4 (e.g., Yervoy[®], Imjudo[®]).
- NCCN grading of pruritus
 - G1: Mild or localized
 - G2: Moderate. Intense or widespread; intermittent; skin changes from scratching (e.g., edema, papulation, excoriations, lichenification, oozing/crusts); limiting instrumental activities of daily living (ADLs)
 - G3: Severe. Intense or widespread; constant; limiting self-care ADLs or sleep
- NCCN grading of bullous dermatitis
 - G1: Asymptomatic; blisters covering < 10% BSA
 - G2: Blisters covering 10%-30% BSA; painful blisters; limiting instrumental ADLs
 - G3: Blisters covering > 30% BSA; limiting self-care ADLs
 - G4: Blisters covering > 30% BSA; associated with fluid or electrolyte abnormalities; intensive care unit (ICU) care or burn unit indicated

Appendix F: Numerical Rating Scale

- The Peak Pruritus Numerical Rating Scale (PP-NRS) and the Worst Itch Numeric Rating Scale (WI-NRS) are single-item, patient-reported outcome measures for assessing the maximum severity of itch in people with pruritic skin disorders. The PP-NRS and WI-NRS assess the intensity of itch “at the worst moment during the previous 24 hours” on a scale of 0 (“no itch”) to 10 (“worst itch imaginable”).

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Moderate-to-severe atopic dermatitis	<i>Adults:</i> Initial dose of 600 mg SC followed by 300 mg SC every other week <i>Adolescents 6-17 years of age:</i> • Body weight 15 to < 30 kg: Initial dose of 600 mg SC followed by 300 mg SC every 4 weeks • Body weight 30 kg to < 60 kg: Initial dose of 400 mg SC followed by 200 mg SC every other week • Body weight $\geq$ 60 kg: Initial dose of 600 mg SC followed by 300 mg SC every other week <i>Pediatrics 6 months - 5 years of age:</i> • Body weight 5 to < 15 kg: 200 mg SC every 4 weeks • Body weight 15 to < 30 kg: 300 mg SC every 4 weeks	See regimen
Moderate-to-severe asthma	<i>Adults and adolescents (12 years and older):</i> Initial dose of 400 mg SC followed by 200 mg SC every other week; or Initial dose of 600 mg SC followed by 300 mg SC every other week For patients requiring concomitant oral corticosteroids or with co-morbid moderate-to-severe atopic dermatitis for which Dupixent is indicated, start with an initial dose of 600 mg SC followed by 300 mg SC every other week <i>Adolescents 6-11 years of age:</i> • Body weight 15 to < 30 kg: Initial dose and subsequent dose of 300 mg SC every four weeks • Body weight $\geq$ 30 kg: Initial dose and subsequent dose of 200 mg SC every other week For pediatric patients (6 to 11 years old) with asthma and co-morbid moderate-to-severe atopic dermatitis, follow the recommended adolescent atopic dermatitis dosing, which includes an initial loading dose	See regimen

Indication	Dosing Regimen	Maximum Dose
CRSwNP	300 mg SC every other week	300 mg every other week
EoE	<i>Adult and pediatric patients ≥ 1 year of age, weight ≥ 15 kg:</i> • Body weight 15 to < 30 kg: 200 mg SC every other week • Body weight 30 to < 40 kg: 300 mg SC every other week • Body weight ≥ 40 kg: 300 mg SC every week	300 mg/week
PN	Initial dose of 600 mg SC followed by 300 mg SC every other week	See regimen
COPD	300 mg SC every other week	300 mg SC every other week
CSU	Age ≥ 18 years: • Initial (one-time) dose: 600 mg SC • Maintenance dose: 300 mg SC every other week Age 12-17 years: • Initial (one-time) dose: ○ Weight ≥ 60 kg: 600 mg SC ○ Weight 30 to < 60 kg: 400 mg SC • Maintenance dose: ○ Weight ≥ 60 kg: 300 mg SC every other week ○ Weight 30 to < 60 kg: 200 mg SC every other week	See regimen
BP	Initial dose of 600 mg SC followed by 300 mg SC every other week	See regimen

VI. Product Availability*

- Pre-filled syringes with needle shield for injection: 100 mg/0.67 mL, 200 mg/1.14 mL, 300 mg/2 mL
- Pre-filled pen: 200 mg/1.14 mL, 300 mg/2 mL

**The pre-filled pen is for use in adult and pediatric patients aged 2 years and older, while the pre-filled syringe is for use in adult and pediatric patients aged 6 months and older. In pediatric patients 12 to 17 years of age, Dupixent should be administered under the supervision of an adult. In pediatric patients 6 months to less than 12 years of age, Dupixent should be administered by a caregiver.*

VII. References

1. Dupixent Prescribing Information. Bridgewater, NJ: Regeneron Pharmaceuticals, Inc. June 2025. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761055s070lbl.pdf. Accessed June 25, 2025.
2. Micromedex[®] Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed November 25, 2024.

Atopic dermatitis

3. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *New England Journal of Medicine*. 2016; 375: 2335-48.
4. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. *J Am Acad Dermatol*. 2023;89(1):e1-e20.
5. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. *Ann Allergy Asthma Immunol*. 2024;132(3):274-312.
6. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. *J Am Acad Dermatol*. Published online November 3, 2023.
7. Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. *J Eur Acad Dermatol Venereol*. 2020 Dec;34(12):2717-2744.
8. Leshem YA, Hajar T, Hanifin JM, et al. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. *British Journal of Dermatology* 2015; 172(5):1353-1357.

Asthma

9. National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Available at <http://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines>. Accessed November 5, 2023.
10. National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group: 2020 Focused Updates to the Asthma Management Guidelines. Bethesda, MD: National Heart, Lung, and Blood Institute, 2020. Available at <https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates>. Accessed November 5, 2023.
11. Global Initiative for Asthma. Global strategy for asthma management and prevention (2024 update). Available from: www.ginasthma.org. Accessed November 25, 2024.
12. Global Initiative for Asthma. Difficult-to-treat and severe asthma in adolescent and adult patients – diagnosis and management, v5.0 November 2024. Available at: www.ginasthma.org. Accessed November 25, 2024.

CRSwNP

13. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. *Otolaryngology–Head and Neck Surgery* 2015, Vol. 152(2S) S1–S39.
14. Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. *Ann Allergy Asthma Immunol* 2014. 113:347-85.

15. Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. doi: 10.1111/all.13875.
16. Han JK, Bosson JV, Cho SH, et al. Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps. *Int Forum Allergy Rhinol.* 2021;1-10. Available at: <https://onlinelibrary.wiley.com/doi/10.1002/alr.22851>. Accessed October 25, 2022.
17. Rank MA, Chu DK, Bognanni A, et al. The Joint Task Force on practice parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. *J Allergy Clin Immunol.* 2023;151(2):386-398.

EoE

18. Dellon ES, Liacouras CA, Molina-Infante J et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE conference. *Gastroenterology.* 2018; 155: 1022–1033.
19. Hiran I, Chan, ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. *Gastroenterology.* 2020; 158(6): 1776-1786.

PN

20. Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. *J Am Acad Dermatol.* 2021; 84(3): 747-760.
21. Sanofi. Study of dupilumab for the treatment of patients with prurigo nodularis, inadequately controlled on topical prescription therapies or when those therapies are not advisable (LIBERTY-PN PRIME). *ClinicalTrials.gov.* Available at: <https://clinicaltrials.gov/ct2/show/NCT04183335>. Accessed November 7, 2023.
22. Sanofi. Study of dupilumab for the treatment of patients with prurigo nodularis, inadequately controlled on topical prescription therapies or when those therapies are not advisable (PRIME2). *ClinicalTrials.gov.* Available at: <https://clinicaltrials.gov/ct2/show/NCT04202679>. Accessed November 7, 2023.

COPD

23. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. *N Engl J Med.* 2023;389(3):205-214. doi:10.1056/NEJMoa2303951.
24. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. *N Engl J Med.* 2024;390(24):2274-2283. doi:10.1056/NEJMoa2401304.
25. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 report). Available at: <http://www.goldcopd.org>. Accessed November 30, 2024.

Immunotherapy-related Pruritus

26. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at www.nccn.org. Accessed November 25, 2024.
27. National Comprehensive Cancer Network. Management of Immunotherapy-Related Toxicities Version 2.2024. Available at https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Accessed November 25, 2024.

CSU

28. Fine LM, Bernstein JA. Guideline of chronic urticaria beyond. Allergy Asthma Immunol Res. 2016 September; 8(5): 396-403.
29. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria (2018 revision). Allergy. 2018; 73: 1393-1414.
30. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022 Mar; 77(3): 734-766.
31. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014; 133(5): 1270-1277.

BP

32. Murrell DF, Joly P, Werth VP, et al. Study design of a phase 2/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT. Adv Ther. 2024 Jul; 41(7): 2991-3002.
33. Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022 Oct; 36(10): 1689-1704.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPSC Codes	Description
C9399; J3590	Unclassified drugs or biologicals

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2021 annual review: no significant changes; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated.	10.26.20	02.21
For nasal polyps, specified that one of the tried intranasal steroids must be Xhance and modified trial duration from 8 weeks to 4 weeks per 2021 consensus panel treatment algorithm; RT4: added newly approved 200 mg/1.14 mL pre-filled pen.	06.16.21	08.21
1Q 2022 annual review: RT4: expanded age to 6+ years old for asthma and added new 100 mg prefilled syringe formulation; for asthma continuation criteria, defined adherence as PDC of 0.8; added Legacy WellCare line of business (WCG.CP.PHAR.336 to retire); added “Acute bronchospasm or status asthmaticus” to section III as indications for which coverage is not authorized per PI; references reviewed and updated.	11.16.21	02.22

Reviews, Revisions, and Approvals	Date	P&T Approval Date
RT4: criteria added for new FDA indication of EoE and pediatric age expansion in AD; for AD redirection to oral immunosuppressants, added minimum age of 2 years; for all indications, added Tezspire as an agent with which Dupixent should not be used concurrently.	07.13.22	08.22
Template changes applied to other diagnoses/indications and continued therapy section.	09.21.22	
For AD indication: clarified that topical corticosteroids requirement is for corticosteroids of different molecular identities and expanded examples of medium to very high potency topical corticosteroids in Appendix B; removed low potency topical corticosteroids from Appendix B.	11.04.22	
1Q 2023 annual review: RT4: criteria added for new FDA indication of PN; for all indications, modified list of agents for which concurrent use is not allowed to include non-asthma biologic immunomodulators and JAK inhibitors; for product availability, updated age limits and recommendations for pre-filled pens vs syringes; references reviewed and updated.	02.01.23	02.23
Per February SDC, for CRSwNP modified requirement from three intranasal steroids to require only two.	02.21.23	05.23
1Q 2024 annual review: for atopic dermatitis removed oral systemic therapy step criterion per updated guideline and competitor analysis; added off-label indication and criteria for immunotherapy-related pruritus per NCCN; references reviewed and updated. RT4: updated EoE indication to reflect pediatric extension to 1 year and older, weighing at least 15 kg.	02.12.24	02.24
Per March SDC, HIM line of business removed as separate criteria is required; for asthma and atopic dermatitis added reference to “Refer to HIM.PA.SP69 for California Exchange Plans and refer to NY.HIM.SP69 for NY CHIP Plans”; for Asthma initial approval criteria, added allowance for emergency room visit and removed intubation option.	03.26.24	05.24
Clarified that “California Commercial Exchange Plans” refers to “California Exchange Plans.”	07.31.24	
RT4: Updated approved indication to include pediatric patients aged 12 years and older for chronic rhinosinusitis with nasal polyps (CRSwNP). RT4: added newly approved COPD indication to criteria. For prurigo nodularis initial approval criteria, updated diagnosis criteria from “WI-NRS $\geq$ 7 on a scale of 0 to 10” to “Numeric rating scale $\geq$ 7 on a scale of 0 (“no itch”) to 10 (“worst imaginable itch”) (e.g., Peak Pruritus Numeric Rating Scale,	11.06.24	12.24

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Worst Itch-Numeric Rating Scale)” to align with Nemludio criteria.		
1Q 2025 annual review: for immunotherapy-related pruritus per NCCN, removed “refractory” for G3 pruritus, added requirement for no response to 1 month of gabapentinoid therapy for severe pruritus, removed requirement for increased IgE level, and added indication for immunotherapy-related bullous dermatitis; references reviewed and updated. Per December SDC, commercial line of business removed as separate criteria is required; for CRSwNP, added disclaimer statement “Refer to NY.HIM.SP69 for NY CHIP Plans.”	12.02.24	02.25
RT4: added new indication for CSU per updated prescribing information. Per SDC: for COPD, revised postbronchodilator FEV ₁ requirement from 30-70% to 20-80% to align with Nucala.	06.09.25	
RT4: added new indication for BP per updated prescribing information and P&T-approved clinical guidance.	06.25.25	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or

regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.